Literature DB >> 28453463

The IGF-I/JAK2-STAT3/miR-21 signaling pathway may be associated with human renal cell carcinoma cell growth.

Ying Su1, An Zhao2, Guoping Cheng1, Jingjing Xu1, Enming Ji1, Wenyong Sun1.   

Abstract

BACKGROUND: Renal cell carcinoma (RCC) is the highest mortality rate of the genitourinary cancers, and the treatment options are very limited. Thus, identification of molecular mechanisms underlying RCC tumorigenesis, is critical for identifying biomarkers for RCC diagnosis and prognosis.
OBJECTIVE: To validate whether the IGF-I/JAK2-STAT3/miR-21 signaling pathway is associated with human RCC cell growth.
METHODS: qRT-PCR and Western blotting were used to detect the mRNA and protein expression levels, respectively. The MTT assay was performed to determine cell survival rate. The Annexin V-FITC/PI apoptosis detection kit was used to detect cell apoptosis. We employed RCC tissues and cell lines (A498; ACHN; Caki-1; Caki-2 and 786-O) in the study. IGF-I, and its inhibitor (NT-157) were administrated to detect the effects of IGF-I on the expression of miR-21 and p-JAK2. JAK2 inhibitor (AG490), and si-STAT3 were used to detect the effects of JAK2/STAT3 signaling pathway on the expression of miR-21.
RESULTS: In our study, we firstly showed that the expression levels of IGF-I and miR-21 were up-regulated in RCC tissues and cell lines. After exogenous IGF-I treatment, the expression levels of miR-21, p-IGF-IR and p-JAK2 were significantly increased, whereas NT-157 treatment showed the reversed results. Further study indicated that JAK2 inhibitor or si-STAT3 significantly reversed the IGF-I-induced miR-21 expression level. Finally, we found that IGF-I treatment significantly prompted human RCC cell survival and inhibited cell apoptosis, and NT-157 treatment showed the reversed results.
CONCLUSIONS: The IGF-I/JAK2-STAT3/miR-21 signaling pathway may be associated with human RCC cell growth.

Entities:  

Keywords:  IGF-I; JAK2-STAT3; miR-21; renal cell carcinoma

Mesh:

Substances:

Year:  2017        PMID: 28453463     DOI: 10.3233/CBM-160449

Source DB:  PubMed          Journal:  Cancer Biomark        ISSN: 1574-0153            Impact factor:   4.388


  5 in total

1.  Heterogeneity of Platelet Derived Growth Factor Pathway Gene Expression Profile Defines Three Distinct Subgroups of Renal Cell Carcinomas.

Authors:  Adela Maria Ferician; Ovidiu Catalin Ferician; Andrei Dragos Cumpanas; Patricia Lorena Berzava; Alexandru Nesiu; Ariana Barmayoun; Anca Maria Cimpean
Journal:  Cancer Genomics Proteomics       Date:  2022 Jul-Aug       Impact factor: 3.395

2.  Mesyl phosphoramidate backbone modified antisense oligonucleotides targeting miR-21 with enhanced in vivo therapeutic potency.

Authors:  Olga A Patutina; Svetlana K Gaponova Miroshnichenko; Aleksandra V Sen'kova; Innokenty A Savin; Daniil V Gladkikh; Ekaterine A Burakova; Alesya A Fokina; Mikhail A Maslov; Elena V Shmendel'; Mattew J A Wood; Valentin V Vlassov; Sidney Altman; Dmitry A Stetsenko; Marina A Zenkova
Journal:  Proc Natl Acad Sci U S A       Date:  2020-12-07       Impact factor: 12.779

3.  Activation of the STAT3/microRNA-21 pathway participates in angiotensin II-induced angiogenesis.

Authors:  Li-Yuan Chen; Xue Wang; Xiao-Long Qu; Li-Na Pan; Ze-Yang Wang; Yong-Hui Lu; Hou-Yuan Hu
Journal:  J Cell Physiol       Date:  2019-04-04       Impact factor: 6.384

4.  Adipogenic Transdifferentiation and Regulatory Factors Promote the Progression and the Immunotherapy Response of Renal Cell Carcinoma: Insights From Integrative Analysis.

Authors:  Shuai Wang; Xiyi Wei; Chengjian Ji; Yichun Wang; Xi Zhang; Rong Cong; Ninghong Song
Journal:  Front Oncol       Date:  2022-03-09       Impact factor: 6.244

5.  AG490, a JAK2-specific inhibitor, downregulates the expression and activity of organic anion transporter-3.

Authors:  Jinghui Zhang; Chenchang Liu; Guofeng You
Journal:  J Pharmacol Sci       Date:  2018-02-08       Impact factor: 3.337

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.